Stock AB AB SCIENCE
Add to a list
To use this feature you must be a member
Log inSign up

News AB Science

Equities

AB

FR0010557264

Market Closed - Euronext Paris
Other stock markets
 11:35:15 2024-04-26 am EDT 		5-day change 1st Jan Change
1.936 EUR +2.76% Intraday chart for AB Science -2.71% -45.54%
Apr. 04 AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada MT
Apr. 03 AB Science: reconsideration possible for masitinib in ALS CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada
MT
AB Science: reconsideration possible for masitinib in ALS
CF
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
GL
AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS
CI
AB Science: encouraging results for masitinib
CF
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
GL
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
AQ
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
GL
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
AQ
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
GL
Transcript : AB Science S.A. - Special Call
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
GL
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
GL
AB Science: share price falls, negative opinion in Canada
CF
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
GL
AB Science: share price falls, CHMP verdict postponed
CF
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
GL
AB Science: medical use patent for masitinib
CF
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
GL
AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AB Stock
  4. News AB Science